Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

Müller, Dafne

doi:10.1007/s40259-022-00573-3

Cited by 19 publications

(13 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given FcyRIIB-mediated inhibition of ADCC, minimal to no engagement to inhibitory FcyRs should be strived at. Alternative approaches to enhance co-stimulatory receptor multimerisation could still consist of biAbs or state-of-the-art Fc-coupled fusion proteins ( 240 ). Moreover, adequate dosing regimen should be determined for patients taking in situ TIL activation status into account.…”

Section: Future Application Of Ics-mediated Agonistic Abs In Plc Mana...mentioning

confidence: 99%

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Rakké,

Buschow,

IJzermans

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the first and second most common primary liver cancer (PLC). For decades, systemic therapies consisting of tyrosine kinase inhibitors (TKIs) or chemotherapy have formed the cornerstone of treating advanced-stage HCC and CCA, respectively. More recently, immunotherapy using immune checkpoint inhibition (ICI) has shown anti-tumour reactivity in some patients. The combination regimen of anti-PD-L1 and anti-VEGF antibodies has been approved as new first-line treatment of advanced-stage HCC. Furthermore, gemcibatine plus cisplatin (GEMCIS) with an anti-PD-L1 antibody is awaiting global approval for the treatment of advanced-stage CCA. As effective anti-tumour reactivity using ICI is achieved in a minor subset of both HCC and CCA patients only, alternative immune strategies to sensitise the tumour microenvironment of PLC are waited for. Here we discuss immune checkpoint stimulation (ICS) as additional tool to enhance anti-tumour reactivity. Up-to-date information on the clinical application of ICS in onco-immunology is provided. This review provides a rationale of the application of next-generation ICS either alone or in combination regimen to potentially enhance anti-tumour reactivity in PLC patients.

show abstract

Section: Future Application Of Ics-mediated Agonistic Abs In Plc Mana...mentioning

confidence: 99%

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Rakké,

Buschow,

IJzermans

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The exploration and deployment of therapeutics targeting Tregs are extensive, chiefly because these cells express an array of receptors on their surface. The most utilized are agonists of the TNFR superfamily and antagonists of immune checkpoint inhibitors ( 230 , 231 ). These modulators alleviate autoimmune conditions and bolster anti-tumor responses by influencing Treg function.…”

Section: Potential Of Treg-based Immunotherapymentioning

confidence: 99%

Regulation of Treg cells by cytokine signaling and co-stimulatory molecules

Zong,

Deng,

Chong

2024

Front. Immunol.

View full text Add to dashboard Cite

CD4+CD25+Foxp3+ regulatory T cells (Tregs), a vital component of the immune system, are responsible for maintaining immune homeostasis and preventing excessive immune responses. This review explores the signaling pathways of the cytokines that regulate Treg cells, including transforming growth factor beta (TGF-β), interleukin (IL)-2, IL-10, and IL-35, which foster the differentiation and enhance the immunosuppressive capabilities of Tregs. It also examines how, conversely, signals mediated by IL-6 and tumor necrosis factor -alpha (TNF-α) can undermine Treg suppressive functions or even drive their reprogramming into effector T cells. The B7 family comprises indispensable co-stimulators for T cell activation. Among its members, this review focuses on the capacity of CTLA-4 and PD-1 to regulate the differentiation, function, and survival of Tregs. As Tregs play an essential role in maintaining immune homeostasis, their dysfunction contributes to the pathogenesis of autoimmune diseases. This review delves into the potential of employing Treg-based immunotherapy for the treatment of autoimmune diseases, transplant rejection, and cancer. By shedding light on these topics, this article aims to enhance our understanding of the regulation of Tregs by cytokines and their therapeutic potential for various pathological conditions.

show abstract

“…While limited studies have been conducted to investigate the role of DNA methylation as a predictive biomarker in HNSCC, several recent studies suggested DNA methylation as a potential predictive biomarker in HNSCC particularly in immunotherapy. The tumor necrosis factor receptor superfamily members 4 (TNFRSF4, OX40) and 18 (TNFRSF18, GITR, AITR) have been under investigation as potential targets for the immunotherapy of various cancers, including HNSCC [49,50]. A study by Loick et al [49] investigated a detailed description of the DNA methylation landscape within GITR and OX40 (both located in close proximity on chromosome 1 p36.33 in HNSCC) [49].…”

Section: Role Of Dna Methylation Profiles In Relation To Response In ...mentioning

confidence: 99%

Role of DNA Methylation Profiles as Potential Biomarkers and Novel Therapeutic Targets in Head and Neck Cancer

Burkitt

2023

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with high mortality. The main reasons for treatment failure are a low rate of early diagnosis, high relapse rates, and distant metastasis with poor outcomes. These are largely due to a lack of diagnostic, prognostic, and predictive biomarkers in HNSCC. DNA methylation has been demonstrated to play an important role in the pathogenesis of HNSCC, and recent studies have also valued DNA methylation as a potential biomarker in HNSCC. This review summarizes the current knowledge on DNA methylation profiles in HPV-positive and HPV-negative HNSCC and how these may contribute to the pathogenesis of HNSCC. It also summarizes the potential value of DNA methylation as a biomarker in the diagnosis, prognosis, and prediction of the response to therapy. With the recent immunotherapy era in head and neck treatment, new strategies to improve immune responses by modulating TIMEs have been intensely investigated in early-phase trials. Therefore, this study additionally summarizes the role of DNA methylation in the regulation of TIMEs and potential predictive immunotherapy response biomarkers. Finally, this study reviews ongoing clinical trials using DNA methylation inhibitors in HNSCC.

show abstract

Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

Cited by 19 publications

References 72 publications

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Regulation of Treg cells by cytokine signaling and co-stimulatory molecules

Role of DNA Methylation Profiles as Potential Biomarkers and Novel Therapeutic Targets in Head and Neck Cancer

Contact Info

Product

Resources

About